NORTH CHICAGO, Ill. — AbbVie has begun construction of a new active pharmaceutical ingredient (API) manufacturing plant at its headquarters campus in North Chicago, marking a major milestone in the company’s U.S. manufacturing expansion.
The state-of-the-art facility, announced on September 29, will focus on the production of medicines for immunology, oncology, and neuroscience. AbbVie stated that the site is expected to be fully operational by 2027 and will facilitate API production for select products from Europe and Asia in the U.S.
“Today’s groundbreaking is an important milestone in AbbVie’s ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the U.S.,” said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. “Over the next decade, AbbVie plans to invest more than $10 billion in capital to add multiple new U.S. manufacturing plants and improve the lives of millions of patients in the U.S. and worldwide who depend on our medicines.”
The $195 million investment in North Chicago will create new jobs and expand AbbVie’s existing U.S. manufacturing footprint, which currently employs more than 6,000 people across 11 sites. Nationwide, AbbVie employs 28,000 people, with 11,000 based in Illinois.
AbbVie said the new facility underscores its commitment to U.S. production and to Illinois, where it develops and manufactures medicines used worldwide.
